Jatakanon 1998.

Methods	Setting: UK, hospital outpatient clinic Length of intervention period: 4 weeks Randomisation: yes, method not stated Allocation concealment: yes Design: crossover with 4 week washout period Masking: double blind Excluded: not stated Withdrawals: stated (none) Baseline characteristics: comparable Jadad score=4
Participants	10 adults: 2M 8F Age range: 24‐36 years Inclusion criteria: Diagnosis of asthma by chest physician with a history of wheezing and chest tightness FEV1 (% predicted) > 80 Methacholine BHR (PC20 FEV1) 4 mg/ml or less Exclusion criteria: Previous inhaled or oral corticosteroid use Asthma exacerbation within the last 12 months
Interventions	BUD: 800 mcg 2xdaily (1600 mcg/d) Placebo: 2xdaily Delivery device: Turbohaler DPI
Outcomes	FEV1 Methacholine BHR (PC20 FEV1) Morning PEFR Daytime PEFR variability Daily asthma symptom score Daily beta2 agonist use Sputum eosinophil count Sputum eosinophil cationic protein Sputum tumour necrosis facto‐alpha Exhaled nitric oxide
Notes	Reply from author confirming use of allocation concealment.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Low risk	A ‐ Adequate